The Journal of Urology
Volume 181, Issue 5 , Pages 1994-1997 , May 2009

Opposing Views

  • Ralph W. deVere White

      Affiliations

    • Department of Urology, University of California, Davis School of Medicine, Sacramento, California
    • ,
  • Mark H. Katz

      Affiliations

    • Urologic Oncology, University of Chicago Medical Center, Chicago, Illinois
    • ,
  • Gary D. Steinberg

      Affiliations

    • Urologic Oncology, University of Chicago Medical Center, Chicago, Illinois

References 

  1. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177:437
  2. Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859;[Erratum: N Engl J Med 2003; 349: 1880]
  3. Hall RR Intl Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, MRC Clinical Trials Unit, London, UK. Updated results of a randomized controlled trial of neoadjuvant cisplatin (C) methotrexate (M) and vinblastine (V) chemotherapy for muscle invasive bladder cancer. Proc AM Soc Clin Oncol. 2002;abstract 710
  4. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005
  5. Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Russo P, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience cancer. Cancer. 2008;113:2471
  6. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781
  7. Chamie K, Hu B, deVere White RW and Ellison LM: Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? Unpublished data.
  8. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178:451
  9. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666
  10. Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2008;54:126
  11. Bassi P, Pagano F, Pappagallo P. Neoadjuvant M-VAC of invasive bladder cancer: the G.U.O.N.E. multicenter phase III trial. Eur Urol. 1998;33(suppl.):142
  12. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial (International collaboration of trialists). Lancet. 1999;354:533
  13. Advanced Bladder Cancer Meta-analysis Colloboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927
  14. Lehmann J, Franzaring L, Thuroff J, Wellek S, Stockle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006;97:42
  15. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459
  16. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:189

PII: S0022-5347(09)00387-5

doi: 10.1016/j.juro.2009.02.052

The Journal of Urology
Volume 181, Issue 5 , Pages 1994-1997 , May 2009

Article Tools